Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

PURPOSE: To evaluate the ocular hypotensive efficacy and safety of razuprotafib, a novel Tie2 activator, when used as an adjunct to latanoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: Subjects with OAG or OHT and an unmedicated IOP from ≥22 mm Hg to <36 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Brigell, Mitchell, Withers, Barbara, Buch, Akshay, Peters, Kevin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742526/
https://www.ncbi.nlm.nih.gov/pubmed/34989803
http://dx.doi.org/10.1167/tvst.11.1.7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742526/
https://www.ncbi.nlm.nih.gov/pubmed/34989803
http://dx.doi.org/10.1167/tvst.11.1.7

Ejemplares similares